NCT01059435View on ClinicalTrials.gov

A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

December 13, 2006

Primary Completion Date

July 6, 2007

Study Completion Date

July 6, 2007

Conditions
Osteopenia
Interventions
DRUG

Romosozumab

Administered subcutaneously or intravenously

DRUG

Placebo

Administered subcutaneously or intravenously

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY